United TherapeuticsUTHR +0.99%88 Buyback Yield % is 10.83 as of Jul. 02, 2026, which is 7636% above its 10-year median of 0.14. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $386.42 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 292 Drug Manufacturers companies, United Therapeutics ranks better than 97.95% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
United Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UTHR vs VTRS, NBIX, ZTS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (UTHR) has a Buyback Yield % of 10.83 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on United Therapeutics and its competitors. This is 7636% above median its historical median of 0.14. Over the past decade, United Therapeutics' Buyback Yield % has ranged from 0.04 to 10.83. According to the industry distribution chart, United Therapeutics ranks #6 out of 292 companies in the Drug Manufacturers industry, placing it in the top 2.1%.
Is United Therapeutics' Buyback Yield % too high?
United Therapeutics' current Buyback Yield % of 10.83 is 7636% above median its 10-year median of 0.14. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 10.83. Based on the distribution chart, United Therapeutics ranks #6 out of 292 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Buyback Yield % compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #6 out of 292 companies for Buyback Yield %. This places United Therapeutics in the top 2% of its industry — outperforming the majority of peers. Historically, United Therapeutics' own Buyback Yield % has ranged from 0.04 to 10.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on United Therapeutics and its competitors. United Therapeutics's current Buyback Yield % is 10.83, which is 7636% above median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.42, compared to a current price of $547.30 — trading 41.6% above its estimated fair value. The current Buyback Yield % is 10.83, which is 7636% above median its 10-year median of 0.14. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Buyback Yield % is 10.83 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $547.30 is trading 41.6% above its estimated GF Value™ of $386.42.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
Buyback Yield %: 10.83 (7636% above median its 10-year median of 0.14)
GF Value™: $386.42 vs. price of $547.30 (41.6% above fair value)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
